Related Experiment Video
Updated: Jun 30, 2025
05:26
A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications
Published on: September 16, 2022
3.9K
Liquid biopsy using non-coding RNAs and extracellular vesicles for breast cancer management
Kazuki Hashimoto1, Takahiro Ochiya2, Akihiko Shimomura3
1Department of Breast Surgical Oncology, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-Ku, Tokyo, 162-8655, Japan.
Breast Cancer (Tokyo, Japan)
|March 21, 2024
Summary
Liquid biopsy, utilizing non-coding RNAs and extracellular vesicles, shows promise for non-invasive breast cancer diagnosis. These biomarkers aid in early detection, treatment monitoring, and prognosis assessment.
Area of Science:
- Biomarkers
- Molecular Diagnostics
- Oncology
Background:
- Liquid biopsy offers a non-invasive approach to cancer diagnostics.
- Non-coding RNAs and extracellular vesicles are key components of liquid biopsy.
- Breast cancer management requires accurate and timely diagnostic tools.
Purpose of the Study:
- To examine the role of non-coding RNAs and extracellular vesicles in breast cancer.
- To elucidate their clinical significance in early detection, treatment monitoring, and prognosis.
- To explore their potential in advancing breast cancer diagnostics and therapeutics.
Main Methods:
- Detailed examination of non-coding RNAs in liquid biopsy.
- Analysis of extracellular vesicles in liquid biopsy.
- Review of current literature on their clinical applications in breast cancer.
Main Results:
- Non-coding RNAs and extracellular vesicles demonstrate significant potential as biomarkers.
- These molecules are valuable for non-invasive breast cancer detection and monitoring.
- Their distinct characteristics offer insights into personalized treatment strategies.
Conclusions:
- Liquid biopsy using non-coding RNAs and extracellular vesicles is a promising tool for breast cancer management.
- Further research is expected to enhance their diagnostic and therapeutic capabilities.
- These biomarkers are poised to revolutionize breast cancer care.
